These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 18671473)

  • 1. A new lipoglycopeptide: telavancin.
    Nannini EC; Stryjewski ME
    Expert Opin Pharmacother; 2008 Aug; 9(12):2197-207. PubMed ID: 18671473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telavancin: a novel lipoglycopeptide antimicrobial agent.
    Attwood RJ; LaPlante KL
    Am J Health Syst Pharm; 2007 Nov; 64(22):2335-48. PubMed ID: 17989443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG; Calic D; Schweizer F; Zelenitsky S; Adam H; Lagacé-Wiens PR; Rubinstein E; Gin AS; Hoban DJ; Karlowsky JA
    Drugs; 2010 May; 70(7):859-86. PubMed ID: 20426497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ; Drew RH
    Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
    Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
    Leonard SN; Rybak MJ
    Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
    Van Bambeke F
    Drugs; 2015 Dec; 75(18):2073-95. PubMed ID: 26603874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS; Reyes N; Wiens T; Vanasse N; Skinner R; McCullough J; Kaniga K; Pace J; Thomas R; Shaw JP; Obedencio G; Judice JK
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3043-50. PubMed ID: 15273119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telavancin: a new lipoglycopeptide with multiple mechanisms of action.
    Kanafani ZA
    Expert Rev Anti Infect Ther; 2006 Oct; 4(5):743-9. PubMed ID: 17140351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
    Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
    Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
    Hegde SS; Janc JW
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides.
    Al Jalali V; Zeitlinger M
    Clin Pharmacokinet; 2018 Jul; 57(7):797-816. PubMed ID: 29332251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telavancin: a novel lipoglycopeptide.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2009 Dec; 49(12):1908-14. PubMed ID: 19911938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
    Klinker KP; Borgert SJ
    Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
    Polyzos KA; Mavros MN; Vardakas KZ; Makris MC; Rafailidis PI; Falagas ME
    PLoS One; 2012; 7(8):e41870. PubMed ID: 22916113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L; Antoni T
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
    Draghi DC; Benton BM; Krause KM; Thornsberry C; Pillar C; Sahm DF
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2383-8. PubMed ID: 18443115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
    Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.